LC, the problem with that being said is that it would only be partial information. Without knowing at what point a trial survivor actually left the trial to try another method, how would you know if the other methods positively influenced them or were they affected by the trial? Also, are you talking about ones that are already approved? If you are, MOOT point. Maybe neither/none positively influenced them. You just can't possibly know without ALL of the trial data. Grant it, when you look at the survival rate from ANYTHING available today, NONE is the cure all. I believe that is why it is imperative that subsets be studied !! No one is claiming that DCVAX-L is the "perfect" treatment for every single individual. I certainly do not believe that. What I do believe is that each treatment as well as a combination of treatments benefits each individual differently depending on their status, progression and DNA. It is very well probable that DCVAX benefits one subset or subsets of people and Keytruda and other treatments different subsets. I also believe that combinations may benefit others with different subsets as well. The point being, NO ONE KNOWS until all of the data can be studied!! That's why all these trials are being vigorously worked but I think that what we do know is that they all have different results for different people with different criteria. In the end I would hope that ALL on this board are praying or rooting for better treatments tomorrow than what we have today. I believe that we are far from selecting one method as the "do all" for cancer treatment.
Pumpernickel YuYu.....YuYU……….YuYUYuYuYu…….AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAWWWWWWWWWWWWWWWWWWWWWWWWWWWWWHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHhOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOooooooooooooooooooooooooooooooooooooEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeee!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
Market Data 
Markets 
AI
